Suntrust Banks Inc. raised its stake in Eli Lilly and Company (NYSE:LLY) by 0.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 183,787 shares of the company’s stock after buying an additional 1,595 shares during the quarter. Suntrust Banks Inc.’s holdings in Eli Lilly and were worth $15,123,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in LLY. Airain ltd acquired a new stake in shares of Eli Lilly and in the second quarter valued at approximately $567,000. Buckingham Asset Management LLC raised its holdings in shares of Eli Lilly and by 21.3% in the second quarter. Buckingham Asset Management LLC now owns 3,232 shares of the company’s stock valued at $266,000 after purchasing an additional 568 shares during the last quarter. BSW Wealth Partners raised its holdings in shares of Eli Lilly and by 0.6% in the second quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock valued at $393,000 after purchasing an additional 27 shares during the last quarter. Sumitomo Life Insurance Co. raised its holdings in shares of Eli Lilly and by 4.4% in the second quarter. Sumitomo Life Insurance Co. now owns 32,507 shares of the company’s stock valued at $2,675,000 after purchasing an additional 1,370 shares during the last quarter. Finally, Mirador Capital Partners LP raised its holdings in shares of Eli Lilly and by 5.3% in the second quarter. Mirador Capital Partners LP now owns 12,280 shares of the company’s stock valued at $1,011,000 after purchasing an additional 619 shares during the last quarter. 75.48% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company (NYSE:LLY) opened at $82.49 on Wednesday. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $89.09. The company has a market cap of $91,236.74, a price-to-earnings ratio of 20.26, a price-to-earnings-growth ratio of 1.83 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same period in the previous year, the business posted $0.88 earnings per share. The company’s revenue for the quarter was up 9.0% compared to the same quarter last year. equities analysts predict that Eli Lilly and Company will post 4.22 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be given a dividend of $0.52 per share. The ex-dividend date is Tuesday, November 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.52%. Eli Lilly and’s dividend payout ratio (DPR) is 98.58%.

COPYRIGHT VIOLATION NOTICE: “Suntrust Banks Inc. Increases Holdings in Eli Lilly and Company (LLY)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/11/15/suntrust-banks-inc-increases-holdings-in-eli-lilly-and-company-lly.html.

LLY has been the topic of a number of recent research reports. Leerink Swann downgraded shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $93.00 to $90.00 in a report on Wednesday, July 26th. BMO Capital Markets reiterated an “underperform” rating and issued a $73.00 price objective on shares of Eli Lilly and in a report on Wednesday, July 26th. Oppenheimer Holdings, Inc. downgraded shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price objective on the stock. in a report on Wednesday, July 26th. UBS AG downgraded shares of Eli Lilly and to a “hold” rating and set a $85.00 price objective on the stock. in a report on Wednesday, July 26th. Finally, TheStreet upgraded shares of Eli Lilly and from a “c+” rating to a “b+” rating in a report on Tuesday, July 25th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $89.76.

In other news, SVP Alfonso G. Zulueta sold 2,003 shares of the business’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of the business’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total transaction of $17,796,050.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 772,003 shares of company stock valued at $64,837,441. Company insiders own 0.20% of the company’s stock.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.